(Q45934195)

18 December 2017

title

Hypothalamic-pituitary-adrenocortical system dysregulation and new treatment strategies in depression. (English)

1 reference

18 December 2017

author name string

Cornelius Schüle

1

1 reference

18 December 2017

Thomas C Baghai

2

1 reference

18 December 2017

Daniela Eser

3

1 reference

18 December 2017

Rainer Rupprecht

4

1 reference

18 December 2017

publication date

1 July 2009

1 reference

18 December 2017

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

published in

1 reference

18 December 2017

volume

9

1 reference

18 December 2017

issue

7

1 reference

18 December 2017

page(s)

1005-1019

1 reference

18 December 2017

The corticosteroid receptor hypothesis of depression

cites work

1 reference

Stress, hypercortisolism and corticosteroid receptors in depression: implications for therapy

21 January 2018

1 reference

Cortisol secretion in endogenous depression. I. Basal plasma levels.

21 January 2018

1 reference

The 24-hour profile of adrenocorticotropin and cortisol in major depressive illness.

21 January 2018

1 reference

Twenty-four-hour ACTH and cortisol pulsatility in depressed women

21 January 2018

1 reference

Cortisol, serotonin and depression: all stressed out?

21 January 2018

1 reference

Bio-social origins of depression in the community. Interactions between social adversity, cortisol and serotonin neurotransmission

21 January 2018

1 reference

Adrenal gland enlargement in major depression. A computed tomographic study

21 January 2018

1 reference

Cortisol and corticosterone response after syn-corticotropin in relationship to dexamethasone suppressibility of cortisol

21 January 2018

1 reference

Adrenal cortical responses to low- and high-dose ACTH(1-24) administration in major depressives vs. matched controls.

21 January 2018

1 reference

Elevated Concentrations of CSF Corticotropin-Releasing Factor-Like Immunoreactivity in Depressed Patients

21 January 2018

1 reference

Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression.

21 January 2018

1 reference

Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims

21 January 2018

1 reference

Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects.

21 January 2018

1 reference

Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy. Corticotrophin-releasing factor, beta-endorphin and somatostatin

21 January 2018

1 reference

Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications

21 January 2018

1 reference

The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications

21 January 2018

1 reference

Chronic infusion of a CRH1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats

21 January 2018

1 reference

Differential behavioural effects of chronic infusion of CRH 1 and CRH 2 receptor antisense oligonucleotides into the rat brain.

21 January 2018

1 reference

Corticotropin-releasing factor CRF1, but not CRF2, receptors mediate anxiogenic-like behavior

21 January 2018

1 reference

Corticotropin-releasing hormone receptor (type I) antisense targeting reduces anxiety.

21 January 2018

1 reference

Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1.

21 January 2018

1 reference

Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development

21 January 2018

1 reference

Reduced anxiety-like and cognitive performance in mice lacking the corticotropin-releasing factor receptor 1.

21 January 2018

1 reference

Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress.

21 January 2018

1 reference

Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2.

21 January 2018

1 reference

Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress.

21 January 2018

1 reference

Deletion of crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2.

21 January 2018

1 reference

Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment

21 January 2018

1 reference

Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation.

21 January 2018

1 reference

Adrenal steroid type I and type II receptor binding: estimates of in vivo receptor number, occupancy, and activation with varying level of steroid.

21 January 2018

1 reference

The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders.

21 January 2018

1 reference

The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety

21 January 2018

1 reference

Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment

21 January 2018

1 reference

Antidepressants increase glucocorticoid and mineralocorticoid receptor mRNA expression in rat hippocampus in vivo

21 January 2018

1 reference

Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system.

21 January 2018

1 reference

The combined dexamethasone/CRH test as a potential surrogate marker in depression

21 January 2018

1 reference

Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression. a prospective study

21 January 2018

1 reference

Glucocorticoids and relapse of major depression (dexamethasone/corticotropin-releasing hormone test in relation to relapse of major depression).

21 January 2018

1 reference

Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system?

21 January 2018

1 reference

Reboxetine acutely stimulates cortisol, ACTH, growth hormone and prolactin secretion in healthy male subjects

21 January 2018

1 reference

Neuroendocrine effects of a 20-mg citalopram infusion in healthy males. A placebo-controlled evaluation of citalopram as 5-HT function probe.

21 January 2018

1 reference

The influence of mirtazapine on anterior pituitary hormone secretion in healthy male subjects

21 January 2018

1 reference

Time course of hypothalamic-pituitary-adrenocortical axis activity during treatment with reboxetine and mirtazapine in depressed patients.

21 January 2018

1 reference

The combined dexamethasone/CRH Test (DEX/CRH test) and prediction of acute treatment response in major depression

21 January 2018

1 reference

New insights into the pathogenesis and pathophysiology of depression

21 January 2018

1 reference

The molecular neurobiology of depression

21 January 2018

1 reference

Neuroendocrinological mechanisms of actions of antidepressant drugs

21 January 2018

1 reference

cAMP-dependent phosphorylation system after short and long-term administration of moclobemide

21 January 2018

1 reference

Regulation of corticotropin-releasing factor neuronal systems and hypothalamic-pituitary-adrenal axis activity by stress and chronic antidepressant treatment

21 January 2018

1 reference

Influence of mirtazapine on urinary free cortisol excretion in depressed patients

21 January 2018

1 reference

The effect of cyproheptadine on the release of corticotrophin releasing factor

21 January 2018

1 reference

Histamine H1 and H2 receptor activation stimulates ACTH and beta-endorphin secretion by increasing corticotropin-releasing hormone in the hypophyseal portal blood.

21 January 2018

1 reference

The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects

21 January 2018

1 reference

Neuroendocrine effects of quetiapine in healthy volunteers

21 January 2018

1 reference

Ziprasidone decreases cortisol excretion in healthy subjects

21 January 2018

1 reference

A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression

21 January 2018

1 reference

Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).

21 January 2018

1 reference

Characterization of a 41-Residue Ovine Hypothalamic Peptide That Stimulates Secretion of Corticotropin and β-Endorphin

21 January 2018

1 reference

The anxiolytic effect of the CRH(1) receptor antagonist R121919 depends on innate emotionality in rats.

21 January 2018

1 reference

Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice

21 January 2018

1 reference

The effects of CRF antagonists, antalarmin, CP154,526, LWH234, and R121919, in the forced swim test and on swim-induced increases in adrenocorticotropin in rats

21 January 2018

1 reference

Anxiolytic- and antidepressant-like profile of a new CRF1 receptor antagonist, R278995/CRA0450.

21 January 2018

1 reference

The effects of CRA 1000, a non-peptide antagonist of corticotropin-releasing factor receptor type 1, on adaptive behaviour in the rat.

21 January 2018

1 reference

Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated

21 January 2018

1 reference

Treatment with the CRH1-receptor-antagonist R121919 improves sleep-EEG in patients with depression

21 January 2018

1 reference

Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects

21 January 2018

1 reference

Treatment with a CRH-1-receptor antagonist (R121919) does not affect weight or plasma leptin concentration in patients with major depression

21 January 2018

1 reference

A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression

21 January 2018

1 reference

Regulation of pituitary ACTH secretion during chronic stress

21 January 2018

1 reference

Vasopressin in affective illness

21 January 2018

1 reference

Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: implications for stress adaptation

21 January 2018

1 reference

Vasopressin as a target for antidepressant development: an assessment of the available evidence

21 January 2018

1 reference

A major SNP haplotype of the arginine vasopressin 1B receptor protects against recurrent major depression

21 January 2018

1 reference

Evidence of an association between the vasopressin V1b receptor gene (AVPR1B) and childhood-onset mood disorders

21 January 2018

1 reference

Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.

21 January 2018

1 reference

Evidence that the lateral septum is involved in the antidepressant-like effects of the vasopressin V1b receptor antagonist, SSR149415.

21 January 2018

1 reference

Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154,526, in rodent models of anxiety and depression.

21 January 2018

1 reference

SSR149415, a non-peptide vasopressin V1b receptor antagonist, has long-lasting antidepressant effects in the olfactory bulbectomy-induced hyperactivity depression model.

21 January 2018

1 reference

Antiglucocorticoid treatment of refractory depression with ketoconazole: a case report.

21 January 2018

1 reference

The psychotropic effects of inhibitors of steroid biosynthesis in depressed patients refractory to treatment.

21 January 2018

1 reference

Treatment of major depression with steroid suppressive drugs

21 January 2018

1 reference

Antiglucocorticoid treatment of depression: double-blind ketoconazole

21 January 2018

1 reference

Limited efficacy of ketoconazole in treatment-refractory major depression.

21 January 2018

1 reference

11beta-Hydroxysteroid dehydrogenase in the brain: a novel regulator of glucocorticoid action?

21 January 2018

1 reference

Metyrapone displays antidepressant-like properties in preclinical paradigms.

21 January 2018

1 reference

The relationship between the effects of metyrapone treatment on depressed mood and urinary steroid profiles

21 January 2018

1 reference

Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial

21 January 2018

1 reference

21 January 2018

1 reference

Steroids and brain activity. Essential dialogue between body and mind

21 January 2018

1 reference

Basal plasma dehydroepiandrosterone sulfate level: a possible predictor for response to electroconvulsive therapy in depressed psychotic inpatients.

21 January 2018

1 reference

Elevated salivary dehydroepiandrosterone-sulfate but normal cortisol levels in medicated depressed patients: preliminary findings

21 January 2018

1 reference

Endogenous concentrations of DHEA and DHEA-S decrease with remission of depression in older adults

21 January 2018

1 reference

Differences in adrenal steroid profile in chronic fatigue syndrome, in depression and in health.

21 January 2018

1 reference

Basal plasma hormone levels in depressed perimenopausal women

21 January 2018

1 reference

Plasma testosterone and dehydroepiandrosterone sulfate in male and female patients with dysthymic disorder.

21 January 2018

1 reference

Urinary steroid metabolites and 11beta-hydroxysteroid dehydrogenase activity in patients with unipolar recurrent major depression

21 January 2018

1 reference

Dehydroepiandrosterone Antagonizes the Suppressive Effects of Dexamethasone on Lymphocyte Proliferation*

21 January 2018

1 reference

Anti-glucocorticoid effects of dehydroepiandrosterone (DHEA).

21 January 2018

1 reference

Cortisol/DHEA ratios in depression

21 January 2018

1 reference

Elevation of the cortisol-dehydroepiandrosterone ratio in drug-free depressed patients.

21 January 2018

1 reference

Psychoendocrine antecedents of persistent first-episode major depression in adolescents: a community-based longitudinal enquiry

21 January 2018

1 reference

Cognitive and affective disorders in the elderly: a neuroendocrine study

21 January 2018

1 reference

Influence of sleep deprivation on neuroactive steroids in major depression

21 January 2018

1 reference

Antidepressant treatment and dehydroepiandrosterone sulfate: different effects of amitriptyline and paroxetine

21 January 2018

1 reference

Effects of mirtazapine on dehydroepiandrosterone-sulfate and cortisol plasma concentrations in depressed patients

21 January 2018

1 reference

Dehydroepiandrosterone (DHEA) treatment of depression

21 January 2018

1 reference

Use of dehydroisoandrosterone in psychiatric treatment; a preliminary survey.

21 January 2018

1 reference

Use of dehydroisoandrosterone in psychiatric practice

21 January 2018

1 reference

Dehydroepiandrosterone treatment of midlife dysthymia.

21 January 2018

1 reference

Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression

21 January 2018

1 reference

Long-term low-dose dehydroepiandrosterone oral supplementation in early and late postmenopausal women modulates endocrine parameters and synthesis of neuroactive steroids

21 January 2018

1 reference

Progesterone increase under DHEA-substitution in males

21 January 2018

1 reference

Dehydroepiandrosterone increases hippocampal spine synapse density in ovariectomized female rats

21 January 2018

1 reference

Dehydroepiandrosterone (DHEA) stimulates neurogenesis in the hippocampus of the rat, promotes survival of newly formed neurons and prevents corticosterone-induced suppression

21 January 2018

1 reference

Prospective controlled studies of the behavioral and biological effects of exogenous corticosteroids

21 January 2018

1 reference

Cortisol circadian rhythm alterations in psychotic major depression

21 January 2018

1 reference

Cortisol level predicts executive and memory function in depression, symptom level predicts psychomotor speed

21 January 2018

1 reference

A corticosteroid/dopamine hypothesis for psychotic depression and related states

21 January 2018

1 reference

The use of mifepristone in the treatment of neuropsychiatric disorders

21 January 2018

1 reference

Mifepristone: clinical pharmacology

21 January 2018

1 reference

Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential

21 January 2018

1 reference

RU486 (mifepristone): mechanisms of action and clinical uses

21 January 2018

1 reference

Clinical and biological effects of mifepristone treatment for psychotic depression

21 January 2018

1 reference

21 January 2018

1 reference

Rapid reversal of psychotic depression using mifepristone

21 January 2018

1 reference

An open label trial of C-1073 (mifepristone) for psychotic major depression

21 January 2018

1 reference

Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder

21 January 2018

1 reference

Review of medical abortion using mifepristone in combination with a prostaglandin analogue

21 January 2018

1 reference

Lithium augmentation increases the ACTH and cortisol response in the combined DEX/CRH test in unipolar major depression

21 January 2018

1 reference

Clinical and neurobiological effects of tianeptine and paroxetine in major depression

21 January 2018

1 reference

The use of ketoconazole as an inhibitor of steroid production

21 January 2018

1 reference

24 Hour Urinary Dehydroepiandosterone Sulfate in Unipolar Depression Treated with Cognitive and/or Pharmacotherapy

21 January 2018

1 reference

Antiglucocorticoid treatments for mood disorders

21 January 2018

1 reference

COCI

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD005168.PUB2

12 January 2024

Identifiers

DOI

10.1586/ERN.09.52

1 reference

18 December 2017

PubMed ID

19589050

1 reference

18 December 2017